Beta-amyloid processing and alpha7 neuronal nicotinic acetylcholine receptors in Alzheimer's disease-related mouse models : interactive mechanisms with focus on new drug targets
Author: Hedberg, Monika M
Date: 2009-05-15
Location: Sal 4U Solen, plan 4, Alfred Nobels Allé 8, Karolinska Institutet, Huddinge
Time: 09.00
Department: Institutionen för neurobiologi, vårdvetenskap och samhälle / Department of Neurobiology, Care Sciences and Society
View/ Open:
Thesis (766.1Kb)
Abstract
Accumulation of beta-amyloid (Abeta), neuronal loss and changes in
neurotransmitter systems, in particular the cholinergic system, are
consistent features of Alzheimer s disease (AD). Abeta is thought to play
a critical role in the pathogenesis of AD and it has therefore become a
target of interest as regards a therapeutic approach. The aim of this
work was to investigate how different Abeta peptides influence
neurotransmission in the brains of AD-related mouse models, as well as to
evaluate how drugs, acting via the cholinergic and glutamatergic
neurotransmitter systems, affect these processes.
Three different transgenic mouse models were utilized: APPswe, hAChE-Tg//APPswe and 3xTg-AD mice, which revealed diverse brain Abeta pathologies. The hAChE-Tg//APPswe mice exhibited accelerated plaque pathology and showed, even at early ages, increased levels of insoluble Abeta in their brains compared with age-matched APPswe mice, whereas the latter expressed increased soluble Abeta. The 3xTg-AD mice showed no extracellular Abeta plaques, while intraneuronal APP/Abeta immunostaining was evident in the cortex and the hippocampus. Whereas APPswe mice showed a more pronounced Abeta pathology, with high Abeta levels both in the cortex and the hippocampus, the 3xTg-AD mice showed detectable Abeta peptides solely in the hippocampus.
A biphasic effect was found on cortical alpha7 neuronal nicotinic acetylcholine receptors (nAChRs) in APPswe mice, with an initial decrease at early ages, followed by an increase at later ages, while the N-methyl-D-aspartate (NMDA) receptors showed a persistent increase from a young age. The increased receptor levels probably reflect compensatory mechanisms in response to a high Abeta burden. No changes were found in alpha7 nAChRs in hAChE-Tg//APPswe mice or 3xTg-AD mice.
At a very early age, the APPswe mice expressed increased cortical synaptophysin levels, followed by a persistent decrease. In 3xTg-AD mice, the observed reduction in cortical synaptophysin might be ascribed to the presence of intraneuronal Abeta.
The choice of transgenic mouse model, as well as the stage of Abeta pathology, was shown to strongly affect the outcome of drug treatment. While decreasing cortical insoluble Abeta1−40 and Abeta1−42 in APPswe mice, L(-)-nicotine increased cortical insoluble Abeta1 40 and soluble Abeta1 42 (both enantiomers) in hAChE-Tg//APPswe mice. However, in both mouse models nicotine reduced glial fibrillary acidic protein (GFAP) immunoreactive astrocytes. In APPswe mice, L(-)-nicotine increased hippocampal and cortical alpha7 nAChRs, while D(+)-nicotine treatment resulted in an increase in these receptors in hAChE-Tg//APPswe mice. Huprine X decreased hippocampal insoluble Abeta1−40, the levels of alpha7 nAChRs in the caudate nucleus, and increased cortical synaptophysin levels in 3xTg-AD mice, while only increasing the levels of alpha7 nAChRs in the hippocampi of APPswe mice. Treatment with the current AD drug galantamine increased cortical synaptophysin levels and affected the NMDA receptors, indicating plastic changes in the brain, while memantine reduced cortical levels of membrane-bound amyloid precursor protein (APP), which eventually may decrease Abeta levels.
In conclusion, the diverse forms of Abeta displayed in the mouse models studied gave rise to differences in brain neuropathology, with diverging results regarding synapses and neuronal receptors as well as the outcome of drug treatment. The results in this work clearly highlight the fact that the choice of transgenic mouse model, as well as the stage of Abeta pathology, contribute importantly to the outcome of drug treatment. This emphasizes the importance of using different transgenic mouse models for evaluating the effects of new drug candidates for this devastating disease.
Three different transgenic mouse models were utilized: APPswe, hAChE-Tg//APPswe and 3xTg-AD mice, which revealed diverse brain Abeta pathologies. The hAChE-Tg//APPswe mice exhibited accelerated plaque pathology and showed, even at early ages, increased levels of insoluble Abeta in their brains compared with age-matched APPswe mice, whereas the latter expressed increased soluble Abeta. The 3xTg-AD mice showed no extracellular Abeta plaques, while intraneuronal APP/Abeta immunostaining was evident in the cortex and the hippocampus. Whereas APPswe mice showed a more pronounced Abeta pathology, with high Abeta levels both in the cortex and the hippocampus, the 3xTg-AD mice showed detectable Abeta peptides solely in the hippocampus.
A biphasic effect was found on cortical alpha7 neuronal nicotinic acetylcholine receptors (nAChRs) in APPswe mice, with an initial decrease at early ages, followed by an increase at later ages, while the N-methyl-D-aspartate (NMDA) receptors showed a persistent increase from a young age. The increased receptor levels probably reflect compensatory mechanisms in response to a high Abeta burden. No changes were found in alpha7 nAChRs in hAChE-Tg//APPswe mice or 3xTg-AD mice.
At a very early age, the APPswe mice expressed increased cortical synaptophysin levels, followed by a persistent decrease. In 3xTg-AD mice, the observed reduction in cortical synaptophysin might be ascribed to the presence of intraneuronal Abeta.
The choice of transgenic mouse model, as well as the stage of Abeta pathology, was shown to strongly affect the outcome of drug treatment. While decreasing cortical insoluble Abeta1−40 and Abeta1−42 in APPswe mice, L(-)-nicotine increased cortical insoluble Abeta1 40 and soluble Abeta1 42 (both enantiomers) in hAChE-Tg//APPswe mice. However, in both mouse models nicotine reduced glial fibrillary acidic protein (GFAP) immunoreactive astrocytes. In APPswe mice, L(-)-nicotine increased hippocampal and cortical alpha7 nAChRs, while D(+)-nicotine treatment resulted in an increase in these receptors in hAChE-Tg//APPswe mice. Huprine X decreased hippocampal insoluble Abeta1−40, the levels of alpha7 nAChRs in the caudate nucleus, and increased cortical synaptophysin levels in 3xTg-AD mice, while only increasing the levels of alpha7 nAChRs in the hippocampi of APPswe mice. Treatment with the current AD drug galantamine increased cortical synaptophysin levels and affected the NMDA receptors, indicating plastic changes in the brain, while memantine reduced cortical levels of membrane-bound amyloid precursor protein (APP), which eventually may decrease Abeta levels.
In conclusion, the diverse forms of Abeta displayed in the mouse models studied gave rise to differences in brain neuropathology, with diverging results regarding synapses and neuronal receptors as well as the outcome of drug treatment. The results in this work clearly highlight the fact that the choice of transgenic mouse model, as well as the stage of Abeta pathology, contribute importantly to the outcome of drug treatment. This emphasizes the importance of using different transgenic mouse models for evaluating the effects of new drug candidates for this devastating disease.
List of papers:
I. Unger C, Hedberg MM, Mustafiz T, Svedberg MM, Nordberg A (2005). "Early changes in Abeta levels in the brain of APPswe transgenic mice--implication on synaptic density, alpha7 neuronal nicotinic acetylcholine- and N-methyl-D-aspartate receptor levels." Mol Cell Neurosci 30(2): 218-27
Pubmed
II. Unger C, Svedberg MM, Yu WF, Hedberg MM, Nordberg A (2006). "Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice." J Pharmacol Exp Ther 317(1): 30-6. Epub 2005 Dec 14
Pubmed
III. Hedberg MM, Svedberg MM, Mustafiz T, Yu WF, Mousavi M, Guan ZZ, Unger C, Nordberg A (2008). "Transgenic mice overexpressing human acetylcholinesterase and the Swedish amyloid precursor protein mutation: effect of nicotine treatment." Neuroscience 152(1): 223-33
Pubmed
IV. Hedberg MM, Clos MV, Ratia M, Gonzalez D, Unger Lithner C, Camps P, Muñoz-Torrero D, Badia A, Giménez-Llort L, Nordberg A (2009). "Effect of huprine X on Abeta, synaptophysin, and alpha7 neuronal nicotinic acetyl-choline receptors in the brain of 3xTg-AD and APPswe transgenic mice." (Manuscript)
I. Unger C, Hedberg MM, Mustafiz T, Svedberg MM, Nordberg A (2005). "Early changes in Abeta levels in the brain of APPswe transgenic mice--implication on synaptic density, alpha7 neuronal nicotinic acetylcholine- and N-methyl-D-aspartate receptor levels." Mol Cell Neurosci 30(2): 218-27
Pubmed
II. Unger C, Svedberg MM, Yu WF, Hedberg MM, Nordberg A (2006). "Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice." J Pharmacol Exp Ther 317(1): 30-6. Epub 2005 Dec 14
Pubmed
III. Hedberg MM, Svedberg MM, Mustafiz T, Yu WF, Mousavi M, Guan ZZ, Unger C, Nordberg A (2008). "Transgenic mice overexpressing human acetylcholinesterase and the Swedish amyloid precursor protein mutation: effect of nicotine treatment." Neuroscience 152(1): 223-33
Pubmed
IV. Hedberg MM, Clos MV, Ratia M, Gonzalez D, Unger Lithner C, Camps P, Muñoz-Torrero D, Badia A, Giménez-Llort L, Nordberg A (2009). "Effect of huprine X on Abeta, synaptophysin, and alpha7 neuronal nicotinic acetyl-choline receptors in the brain of 3xTg-AD and APPswe transgenic mice." (Manuscript)
Issue date: 2009-04-24
Rights:
Publication year: 2009
ISBN: 978-91-7409-442-8
Statistics
Total Visits
Views | |
---|---|
Beta-amyloid ...(legacy) | 809 |
Beta-amyloid ... | 133 |
Total Visits Per Month
October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
---|---|---|---|---|---|---|---|
Beta-amyloid ... | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
File Visits
Views | |
---|---|
thesis.pdf(legacy) | 348 |
thesis.pdf | 155 |
thesis.pdf.txt(legacy) | 2 |
Top country views
Views | |
---|---|
United States | 390 |
China | 65 |
Sweden | 64 |
Germany | 52 |
South Korea | 25 |
Russia | 19 |
Finland | 16 |
United Kingdom | 13 |
Denmark | 10 |
France | 9 |
Top cities views
Views | |
---|---|
Sunnyvale | 47 |
Romeo | 36 |
Seoul | 25 |
Beijing | 24 |
Kiez | 20 |
Ballerup | 9 |
Helsinki | 8 |
Des Moines | 7 |
Stockholm | 7 |
Ashburn | 6 |